ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Dick C ChanGerald F Watts
Published in: Current opinion in lipidology (2024)
Novel agents targeting ANGPTL3 and apoC-III can correct HTG and potentially lower risk of ASCVD in patients with HTG. The long-term safety and cost-effectiveness of these agents await confirmation in ongoing and future studies.